Search Results - "Marder, K."

Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort by UC, E. Y, MCDERMOTT, M. P, MARDER, K. S, ANDERSON, S. W, LITVAN, I, COMO, P. G, AUINGER, P, CHOU, K. L, GROWDON, J. C

“…To investigate the incidence of and risk factors for cognitive impairment in a large, well-defined clinical trial cohort of patients with early Parkinson…”
Get full text

Updated research nosology for HIV-associated neurocognitive disorders by ANTINORI, A, ARENDT, G, GISSLEN, M, GRANT, I, HEATON, R. K, JOSEPH, J, MARDER, K, MARRA, C. M, MCARTHUR, J. C, NUNN, M, PRICE, R. W, PULLIAM, L, BECKER, J. T, ROBERTSON, K. R, SACKTOR, N, VALCOUR, V, WOJNA, V. E, BREW, B. J, BYRD, D. A, CHERNER, M, CLIFFORD, D. B, CINQUE, P, EPSTEIN, L. G, GOODKIN, K

“…In 1991, the AIDS Task Force of the American Academy of Neurology published nomenclature and research case definitions to guide the diagnosis of neurologic…”
Get full text

Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis by AARSLAND, D, BRONNICK, K, SANTANGELO, G, FOLTYNIE, T, JANVIN, C, LARSEN, J. P, BARKER, R. A, EMRE, M, WILLIAMS-GRAY, C, WEINTRAUB, D, MARDER, K, KULISEVSKY, J, BURN, D, BARONE, P, PAGONABARRAGA, J, ALLCOCK, L

“…In studies of mild cognitive impairment (MCI) in Parkinson disease (PD), patients without dementia have reported variable prevalences and profiles of MCI,…”
Get full text

Alpha galactosidase A activity in Parkinson's disease by Alcalay, R.N., Wolf, P., Levy, O.A., Kang, U.J., Waters, C., Fahn, S., Ford, B., Kuo, S.H., Vanegas, N., Shah, H., Liong, C., Narayan, S., Pauciulo, M.W., Nichols, W.C., Gan-Or, Z., Rouleau, G.A., Chung, W.K., Oliva, P., Keutzer, J., Marder, K., Zhang, X.K.

“…Glucocerebrosidase (GCase, deficient in Gaucher disease) enzymatic activity measured in dried blood spots of Parkinson's Disease (PD) cases is within healthy…”
Get full text

Developmental malformations in Huntington disease: neuropathologic evidence of focal neuronal migration defects in a subset of adult brains by Hickman, R. A., Faust, P. L., Rosenblum, M. K., Marder, K., Mehler, M. F., Vonsattel, J. P.

“…Neuropathologic hallmarks of Huntington Disease (HD) include the progressive neurodegeneration of the striatum and the presence of Huntingtin (HTT) aggregates…”
Get full text

Cognitive performance of GBA mutation carriers with early-onset PD: The CORE-PD study by ALCALAY, R. N, CACCAPPOLO, E, LOUIS, E, COMELLA, C, COLCHER, A, JENNINGS, D, NANCE, M, BRESSMAN, S, SCOTT, W. K, TANNER, C, MICKEL, S, ANDREWS, H, MEJIA-SANTANA, H, WATERS, C, FAHN, S, COTE, L, FRUCHT, S, FORD, B, REZAK, M, NOVAK, K, FRIEDMAN, J. H, PFEIFFER, R, MARSH, L, TANG, M.-X, HINER, B, SIDEROWF, A, PAYAMI, H, MOLHO, E, FACTOR, S, OTTMAN, R, CLARK, L. N, MARDER, K, ROSADO, L, ORBE REILLY, M, RUIZ, D, ROSS, B, VERBITSKY, M, KISSELEV, S

“…To assess the cognitive phenotype of glucocerebrosidase (GBA) mutation carriers with early-onset Parkinson disease (PD). We administered a neuropsychological…”
Get full text

Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations by PANKRATZ, N, KISSELL, D. K, PAUCIULO, M. W, HALTER, C. A, RUDOLPH, A, PFEIFFER, R. F, MARDER, K. S, FOROUD, T, NICHOLS, W. C

“…Mutations in both alleles of parkin have been shown to result in Parkinson disease (PD). However, it is unclear whether haploinsufficiency (presence of a…”
Get full text

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG by Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., Ulug, A. M., Beal, M. F., Matson, W., Bogdanov, M., Ebbel, E., Zaleta, A., Kaneko, Y., Jenkins, B., Hevelone, N., Zhang, H., Yu, H., Schoenfeld, D., Ferrante, R., Rosas, H. D.

Get full text

Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease by Popat, R. A., Van Den Eeden, S. K., Tanner, C. M., Kamel, F., Umbach, D. M., Marder, K., Mayeux, R., Ritz, B., Ross, G. W., Petrovitch, H., Topol, B., McGuire, V., Costello, S., Manthripragada, A. D., Southwick, A., Myers, R. M., Nelson, L. M.

“…Background and purpose:  In 1‐methyl‐4‐phenyl 1,2,3,6‐tetrahydropyridine animal models of Parkinson’s disease (PD), caffeine protects neurons by blocking the…”
Get full text

Motor signs predict poor outcomes in Alzheimer disease by SCARMEAS, N, ALBERT, M, BELL, K, HONIG, L, STERN, Y, BRANDT, J, BLACKER, D, HADJIGEORGIOU, G, PAPADIMITRIOU, A, DUBOIS, B, SARAZIN, M, WEGESIN, D, MARDER, K

“…To examine whether the presence of motor signs has predictive value for important outcomes in Alzheimer disease (AD). A total of 533 patients with AD at early…”
Get full text

Incidence of and risk factors for HIV-associated distal sensory polyneuropathy by SCHIFITTO, G, MCDERMOTT, M. P, MCARTHUR, J. C, MARDER, K, SACKTOR, N, EPSTEIN, L, KIEBURTZ, K

“…To assess the incidence of and risk factors for distal sensory polyneuropathy (DSP) in a cohort of HIV-infected subjects. We followed 272 subjects semiannually…”
Get full text

Motor signs during the course of Alzheimer disease by SCARMEAS, N, HADJIGEORGIOU, G. M, WEGESIN, D, STERN, Y, PAPADIMITRIOU, A, DUBOIS, B, SARAZIN, M, BRANDT, J, ALBERT, M, MARDER, K, BELL, K, HONIG, L. S

“…Motor signs (MOSIs) are common in Alzheimer disease (AD) and may be associated with rates of cognitive decline, mortality, and cost of care. To describe the…”
Get full text

Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease by CLARK, L. N, ROSS, B. M, FORD, B, FRUCHT, S, OTTMAN, R, MARDER, K, WANG, Y, MEJIA-SANTANA, H, HARRIS, J, LOUIS, E. D, COTE, L. J, ANDREWS, H, FAHN, S, WATERS, C

“…To evaluate the frequency of glucocerebrosidase (GBA) mutations in cases and controls enrolled in the Genetic Epidemiology of Parkinson's Disease (GEPD) study…”
Get full text

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG by HERSCH, S. M, GEVORKIAN, S, ULUG, A. M, BEAL, M. F, MATSON, W, BOGDANOV, M, EBBEL, E, ZALETA, A, KANEKO, Y, JENKINS, B, HEVELONE, N, ZHANG, H, MARDER, K, YU, H, SCHOENFELD, D, FERRANTE, R, ROSAS, H. D, MOSKOWITZ, C, FEIGIN, A, COX, M, COMO, P, ZIMMERMAN, C, LIN, M, ZHANG, L

“…In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well…”
Get full text

Dietary intake in adults at risk for Huntington disease: Analysis of PHAROS Research Participants by MARDER, K, ZHAO, H, EBERLY, S, TANNER, C. M, OAKES, D, SHOULSON, I

“…To examine caloric intake, dietary composition, and body mass index (BMI) in participants in the Prospective Huntington At Risk Observational Study (PHAROS)…”
Get full text

Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia by SEVIGNY, J. J, ALBERT, S. M, PALUMBO, D, KIEBURTZ, K, RIGGS, G, COHEN, B, EPSTEIN, L. G, MARDER, K, MCDERMOTT, M. P, MCARTHUR, J. C, SACKTOR, N, CONANT, K, SCHIFITTO, G, SELNES, O. A, STERN, Y, MCCLERNON, D. R

“…To evaluate whether baseline levels of plasma and CSF HIV RNA, tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein-1 (MCP-1), matrix…”
Get full text

Frequency of LRRK2 mutations in early-and late-onset Parkinson disease by CLARK, L. N, WANG, Y, WATERS, C, FORD, B, FRUCHT, S, OTTMAN, R, MARDER, K, KARLINS, E, SAITO, L, MEJIA-SANTANA, H, HARRIS, J, LOUIS, E. D, COTE, L. J, ANDREWS, H, FAHN, S

“…To evaluate the frequency of leucine-rich repeat kinase gene (LRRK2) mutations and single nucleotide polymorphisms (SNPs) in early-onset Parkinson disease…”
Get full text

Association between mild parkinsonian signs and mild cognitive impairment in a community by LOUIS, E. D, SCHUPF, N, MANLY, J, MARDER, K, TANG, M. X, MAYEUX, R

“…Mild parkinsonian signs (MPS) are associated with prevalent and incident dementia but it is not known whether they are associated with mild cognitive…”
Get full text

The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease by Gan-Or, Z., Amshalom, I., Bar-Shira, A., Gana-Weisz, M., Mirelman, A., Marder, K., Bressman, S., Giladi, N., Orr-Urtreger, A.

“…GBA mutations are among the most common genetic risk factors for Parkinson disease (PD) worldwide. We aimed to identify genetic modifiers of the age at onset…”
Get full text

Weight loss in early stage of Huntington's disease by DJOUSSE, L, KNOWLTON, B, CUPPLES, L. A, MARDER, K, SHOULSON, I, MYERS, R. H

“…Huntington's disease (HD) is an autosomal dominant disease with neurologic manifestations. In transgenic mouse models of HD, weight loss is recognized as a…”
Get full text